Last update 16 May 2025

Product 0405(Novartis)

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms-
Target-
Action-
Mechanism-
Therapeutic Areas
Immune System DiseasesCongenital DisordersSkin and Musculoskeletal Diseases
Active Indication-
Inactive Indication
Mild Atopic DermatitisModerate Atopic DermatitisSevere Atopic Dermatitis
Originator Organization
Novartis Pharma AG
Active Organization-
Inactive Organization
Fougera Pharmaceuticals, Inc.Fougera Pharmaceuticals, Inc.
License Organization-
Drug Highest PhaseDiscontinuedPhase 3
First Approval Date-
Regulation-
Login to view timeline

Related

4
Clinical Trials associated with Product 0405(Novartis)
NCT02176538
/ WithdrawnPhase 3
A Multi-Center, Double-Blind, Randomized, Vehicle-Controlled, Parallel-Group Study Comparing Product 0405 To A Vehicle Control In The Treatment Of Mild To Moderate Atopic Dermatitis In Pediatric Subjects
NCT02176577
/ WithdrawnPhase 3
An Open-Label, Multi-Center Study to Determine the Pharmacokinetics of Product 0405 in the Treatment of Atopic Dermatitis in Adolescent Subjects
NCT02176551
/ WithdrawnPhase 3
A Multi-Center, Double-Blind, Randomized, Vehicle-Controlled, Parallel-Group Study Comparing Product 0405 To A Vehicle Control In The Treatment Of Mild To Moderate Atopic Dermatitis In Pediatric Subjects
100 Clinical Results associated with Product 0405(Novartis)
Login to view more data
100 Translational Medicine associated with Product 0405(Novartis)
Login to view more data
100 Patents (Medical) associated with Product 0405(Novartis)
Login to view more data
100 Deals associated with Product 0405(Novartis)
Login to view more data

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Mild Atopic DermatitisPhase 3-
Fougera Pharmaceuticals, Inc.Fougera Pharmaceuticals, Inc.
01 Jun 2012
Moderate Atopic DermatitisPhase 3-
Fougera Pharmaceuticals, Inc.Fougera Pharmaceuticals, Inc.
01 Jun 2012
Severe Atopic DermatitisPhase 2
United States
Fougera Pharmaceuticals, Inc.Fougera Pharmaceuticals, Inc.
01 Nov 2010
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date

No Data

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
login
or
view full example data
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
login
or
view full example data
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
login
or
view full example data
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
login
or
view full example data
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free